Kim Fox

Active 1978–2024

78
Papers
18,155
Citations
61
h-index
77
i10-index

Citations

Citations per year for Kim Fox1979: 1 citations1980: 4 citations1981: 1 citations1982: 3 citations1983: 8 citations1984: 7 citations1985: 7 citations1986: 2 citations1987: 6 citations1988: 13 citations1989: 6 citations1990: 14 citations1991: 10 citations1992: 15 citations1993: 6 citations1994: 8 citations1995: 7 citations1996: 18 citations1997: 8 citations1998: 12 citations1999: 17 citations2000: 29 citations2001: 39 citations2002: 31 citations2003: 50 citations2004: 80 citations2005: 74 citations2006: 91 citations2007: 117 citations2008: 79 citations2009: 95 citations2010: 84 citations2011: 101 citations2012: 107 citations2013: 109 citations2014: 98 citations2015: 82 citations2016: 99 citations2017: 88 citations2018: 58 citations2019: 234 citations2020: 237 citations2021: 292 citations2022: 294 citations2023: 270 citations2024: 389 citations2025: 194 citations2026: 16 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,135 citing papers, 19.2% of this breakdownUnited Kingdom: 576 citing papers, 9.7% of this breakdownItaly: 410 citing papers, 6.9% of this breakdownChina: 347 citing papers, 5.9% of this breakdownCanada: 303 citing papers, 5.1% of this breakdownGermany: 300 citing papers, 5.1% of this breakdownFrance: 250 citing papers, 4.2% of this breakdownAustralia: 223 citing papers, 3.8% of this breakdownNetherlands: 201 citing papers, 3.4% of this breakdownSweden: 192 citing papers, 3.3% of this breakdownSpain: 169 citing papers, 2.9% of this breakdownSwitzerland: 130 citing papers, 2.2% of this breakdown
0%19.2%Other 28.3%

Fields

  • Medicine85.1%
  • Biochemistry, Genetics and Molecular Biology5%
  • Engineering2.1%
  • Neuroscience1.1%
  • Nursing0.9%
  • Computer Science0.9%
  • Other4.9%

Topics

  • Blood Pressure and Hypertension Studies7%
  • Cardiac Imaging and Diagnostics5.4%
  • Acute Myocardial Infarction Research5%
  • Heart Rate Variability and Autonomic Control4.4%
  • Heart Failure Treatment and Management3.8%
  • Heart rate and cardiovascular health3.5%
  • Other70.9%

Coauthors

All papers

Open in search
  1. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Masao Ishii, Stevo Julius, Yoshihiko Kanno, Sverre E. Kjeldsen, John B. Kostis, Kizuku Kuramoto, Jan Lanke, Edmund J. Lewis, Julia B. Lewis, Michel Lièvre, Lars Lindholm, Stephan Lueders, Stephen MacMahon, Giuseppe Mancia, Masunori Matsuzaki, Maria H. Mehlum, Steven Nissen, Hiroshi Ogawa, Toshio Ogihara, Takayoshi Ohkubo, Christopher R. Palmer, Anushka Patel, Marc Allan Pfeffer, Bertram Pitt, Neil R Poulter, Hiromi Rakugi, Gianpaolo Reboldi, Christopher M. Reid, Giuseppe Remuzzi, Piero Ruggenenti, Takao Saruta, Joachim Schrader, Robert W. Schrier, Peter Sever, Peter Sleight, Jan A. Staessen, Hiromichi Suzuki, Lutgarde Thijs, Kenji Ueshima, Seiji Umemoto, Wiek H. van Gilst, Paolo Verdecchia, Kristian Wachtell, Paul K. Whelton, Lindon Wing, Yoshiki Yui, Salim Yusuf, Alberto Zanchetti, Zhen‐Yu Zhang, Craig S. Anderson, Colin Baigent, Barry M. Brenner, Rory Collins, Dick de Zeeuw, Jacobus Lubsen, Ettore Malacco, Bruce Neal, Vlado Perkovic, Anthony Rodgers, Peter M. Rothwell, Gholamreza Salimi-Khorshidi, Johan Sundström, Fiona Turnbull, Giancarlo Viberti, Ji‐Guang Wang, John Chalmers, Koon Teo, Carl J. Pepine, Barry R. Davis - The Lancet 2021 cited by 1,001

  2. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rury R. Holman, Yutaka Imai, Masao Ishii, Stevo Julius, Yoshihiko Kanno, Sverre E. Kjeldsen, John B. Kostis, Kizuku Kuramoto, Jan Lanke, Edmund J. Lewis, Julia B. Lewis, Michel Lièvre, Lars Lindholm, Stephan Lueders, Stephen MacMahon, Giuseppe Mancia, Masunori Matsuzaki, Maria H. Mehlum, Steven Nissen, Hiroshi Ogawa, Toshio Ogihara, Takayoshi Ohkubo, Christopher R. Palmer, Anushka Patel, Marc Allan Pfeffer, Bertram Pitt, Neil R Poulter, Hiromi Rakugi, Gianpaolo Reboldi, Christopher M. Reid, Giuseppe Remuzzi, Piero Ruggenenti, Takao Saruta, Joachim Schrader, Robert W. Schrier, Peter Sever, Peter Sleight, Jan A. Staessen, Hiromichi Suzuki, Lutgarde Thijs, Kenji Ueshima, Seiji Umemoto, Wiek H. van Gilst, Paolo Verdecchia, Kristian Wachtell, Paul K. Whelton, Lindon Wing, Mark Woodward, Yoshiki Yui, Salim Yusuf, Alberto Zanchetti, Zhen‐Yu Zhang, Craig S. Anderson, Colin Baigent, Barry M. Brenner, Rory Collins, Dick de Zeeuw, Jacobus Lubsen, Ettore Malacco, Bruce Neal, Vlado Perkovic, Anthony Rodgers, Peter M. Rothwell, Gholamreza Salimi-Khorshidi, Johan Sundström, Fiona Turnbull, Giancarlo Viberti, Ji‐Guang Wang, John Chalmers, Barry R. Davis and 2 more - The Lancet 2021 cited by 321

  3. Resting Heart Rate in Cardiovascular Disease

    Authors: , , , , , , , , , - Journal of the American College of Cardiology 2007 cited by 1,063

  4. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study

    Authors: , , , , , , , , , - The Lancet 2016 cited by 483

  5. Ticagrelor in Patients with Stable Coronary Disease and Diabetes

    Authors: , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 cited by 362

  6. Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: the FORECAST randomized trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - European Heart Journal 2021 cited by 161

  7. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)

    Authors: - The Lancet 2003 cited by 2,153

  8. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial

    Authors: , , , , - The Lancet 2008 cited by 1,095

  9. Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure

    Authors: , , , , , - New England Journal of Medicine 2014 cited by 482

  10. Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , R Estacio, Robert Fagard, Kim Fox, Takahiro Fukui, Ajay Gupta, Rury R. Holman, Y. Imai, Masao Ishii, Stevo Julius, Yoshihiko Kanno, Sverre E. Kjeldsen, John B. Kostis, K Kuramoto, Jan Lanke, Edmund J. Lewis, Jeff Lewis, Michel Lièvre, Lars Lindholm, Stephan Lueders, Stephen MacMahon, G. Mancia, M Matsuzaki, Maria H. Mehlum, Steven Nissen, Hiroshi Ogawa, Toshio Ogihara, Takayoshi Ohkubo, C. Palmer, Anushka Patel, Carl J. Pepine, Michael Pfeffer, N. Poulter, Hiromi Rakugi, Gianpaolo Reboldi, Christopher M. Reid, Giuseppe Remuzzi, Piero Ruggenenti, T Saruta, Joachim Schrader, Robert W. Schrier, Peter S. Sever, Peter Sleight, Jan A. Staessen, Hiromichi Suzuki, Lutgarde Thijs, Kenji Ueshima, Seiji Umemoto, Wiek H. van Gilst, Paolo Verdecchia, Kristian Wachtell, Paul K. Whelton, L. Wing, Mark Woodward, Yoshiaki Yui, Salim Yusuf, Alberto Zanchetti, Z Y Zhang, Craig S. Anderson, Colin Baigent, Brenner Bm, Richard Collins, Dick de Zeeuw, Jacobus Lubsen, Ettore Malacco, Bruce Neal, Vlado Perkovic, Bertram Pitt, Anthony Rodgers, Peter M. Rothwell, Gholamreza Salimi-Khorshidi and 4 more - The Lancet Oncology 2021 cited by 104

  11. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Francisco Padrón, R. Passi, Jay Stone, Michael Pursley, Michael D'Urso, Timothy J. Gardner, James Bennett, Khaled Nour, Satinder Saini, Wenwu Zhang, Dharam J. Kumbhani, Dustin Thomas, Dominick J. Angiolillo, Barry Bertolet, Amaury Roman-Miranda, Robert Black, Ramin Manshadi, Carlos Vaca, Antonio Blanco, Mark Napoli, David Brabham, Ayim Akyea-Djamson, Pratik Desai, Sudhir Prasada, Ajit S Khaira, Leslie B. Forgosh, Ira Lieber, Guillermo E. Umpierrez, Dinesh Singal, Juan Luis Londoño, Neil Fraser, Jose Ruiz, Damaris Vega, Lilia Rodriguez, Christopher Brown, Faizullah Syed, Guarav Aggarwala, William Eaves, Michael Foster, Dinesh Gupta, David Avino, Wail Asfour, Glen Tonnessen, Xue‐Qiao Zhao, Narendra Singh, Andrew Brockmyre, Norman Lepor, Nicolas W. Shammas, David R. Blick, Steven Hearne, John Prodafikas, Edgar S. Carell, Mark Izzo, Amin H. Karim, Bosh Zakhary, Mahmoud Atieh, Steven B. Leichter, Charles Meadows, David R. Hotchkiss, Mazen Abu-Fadel, Alan Wiseman, Jeffrey Bander, Mahesh Shah, Subhash Banerjee, Ricky Ganim, Karen S Sopko, Misal Khan, Ramon L. Lloret, Troy Weirick, Rajendra H. Mehta and 1,247 more - The Lancet 2019 cited by 210

  12. Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry

    Authors: , , , , , , , , , , , , , , , , - European Heart Journal 2019 cited by 102

  13. A 'diamond' approach to personalized treatment of angina

    Authors: , , , , , , , , , - Nature Reviews Cardiology 2017 cited by 169

  14. Atherogenic Dyslipidemia and Residual Cardiovascular Risk in Statin-Treated Patients

    Authors: , , , , , , , , , , , , , , , , , , , - Stroke 2014 cited by 109

  15. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial

    Authors: , , , , , - The Lancet 2008 cited by 788

  16. International Observational Analysis of Evolution and Outcomes of Chronic Stable Angina: The Multinational CLARIFY Study

    Authors: , , , , , , , , , - Circulation 2021 cited by 61

  17. Prevalence of Anginal Symptoms and Myocardial Ischemia and Their Effect on Clinical Outcomes in Outpatients With Stable Coronary Artery Disease

    Authors: , , , , , , , , , , , - JAMA Internal Medicine 2014 cited by 146

  18. Heart rate reduction in coronary artery disease and heart failure

    Authors: , - Nature Reviews Cardiology 2016 cited by 109

  19. Geographical variations in the prevalence and management of cardiovascular risk factors in outpatients with CAD: Data from the contemporary CLARIFY registry

    Authors: , , , , , , , , , - European Journal of Preventive Cardiology 2014 cited by 77

  20. Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities

    Authors: , , , , , , , , , , , , , - European Journal of Preventive Cardiology 2021 cited by 38

  21. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials

    Authors: , , , , - The Lancet 2006 cited by 514

  22. Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology

    Authors: , , , , , , , , - European Heart Journal 2006 cited by 391

  23. Anti-anginal drugs–beliefs and evidence: systematic review covering 50 years of medical treatment

    Authors: , , , , , , , , , , - European Heart Journal 2018 cited by 101

  24. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial

    Authors: , , , , , , , - The Lancet 2020 cited by 75